Targeted anti-cancer therapies for renal cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Significant advances in understanding renal cell cancer biology, especially tumor angiogenesis, have enabled targeted therapy development.
• Tumor angiogenesis plays a crucial role in renal cell cancer progression.
• Molecularly targeted therapeutics have emerged as a promising treatment modality.

Purpose of the Study:

• To review single-agent targeted therapies for renal cell cancer.
• To identify therapies targeting specific molecular pathways.
• To assess the clinical benefit and toxicity profiles of these targeted agents.

Main Methods:

• Literature review of single-agent therapies targeting specific pathways.
• Identification of therapies inhibiting: epithelial growth factor receptor, vascular endothelial growth factor receptor, basic fibroblast growth factor receptor, platelet-derived growth factor, nuclear factor-kappabeta, mammalian target of rapamycin (mTOR) pathway, raf kinase pathway, and tyrosine kinase pathway.
• Categorization of therapies into monoclonal antibodies, small molecules, nanopeptides, and immunomodulators.

Main Results:

• Various targeted therapies demonstrated acceptable toxicity profiles.
• Antitumor response, including regression or delayed progression-free survival, ranged from 5% to 71%.
• Distinct fields of clinical research have emerged, including monoclonal antibodies and small molecules.

Conclusions:

• Targeted therapies offer significant clinical benefit in managing renal cell cancer.
• Further basic research is warranted to enhance clinical outcomes.
• Current targeted therapies represent a major advancement in renal cell cancer treatment.